Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01662791 · ClinicalTrials.gov registry record · Phase 3
Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth
A Phase 3 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
NCT01662791: Completed Phase 3 study, sponsored by Mayo Clinic.
NCT01662791 is a Phase 3 study that has completed, run by Mayo Clinic. The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01662791, a Phase 3 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
Study Summary
The potential role of small bowel bacterial overgrowth (SBBO) in weight loss occurring in patients with Parkinson's Disease (PD) has not previously been examined. Our hypothesis was that SBBO is an important contributor to the development of weight loss in individuals with PD. The investigators proposed to 1) examine the role of SBBO in weight loss occurring in patients with PD and 2) determine the response to its treatment with a poorly absorbed antibiotic. The investigators performed a prospective, observational case-control study (Part 1) with an open-label therapeutic component (Part 2). Cases were defined as those PD patients who experienced significant weight loss while Controls were defined as those PD patients who did not experience significant weight loss.
Interventions
- DRUG Rifaximin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01662791
The ClinicalTrials.gov registry entry for NCT01662791 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rifaximin is the first listed.
NCT01662791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01662791 about?
NCT01662791 is a clinical study titled "Weight Loss in Parkinson's Disease and Role of Small Bowel Bacterial Overgrowth". The potential role of small bowel bacterial overgrowth (SBBO) in weight loss occurring in patients with Parkinson's Disease (PD) has not previously been examined. Our hypothesis was that SBBO is an important contributor to the development of weight loss in individuals with PD. The investigators prop...
What is the current status of trial NCT01662791?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2012-09. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01662791?
The interventions under investigation include: Rifaximin (DRUG).
Who is sponsoring clinical trial NCT01662791?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.